A HAMLET patent portfolio has been established, with a number of issued patents, world-wide. Intellectual property rights include patents covering the manufacturing and use of HAMLET and substances derived from HAMLET ‘’second generation drug candidates’’. Patents have been granted in the US, Europe, Asia and Australia. Among the latest patent and patent applications are patents and applications that protect the production and use of recombinantly produced HAMLET, applications that protect the next generation HAMLET substances (peptide drugs), and applications for protection of use of HAMLET for prophylactic purposes.
HAMLET / BAMLET is protected by five patent families